ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc (ARCT)

31.00
-0.60
(-1.90%)
Closed June 15 4:00PM
31.60
0.60
(1.94%)
After Hours: 7:57PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
31.60
Bid
21.00
Ask
43.81
Volume
360,785
30.00 Day's Range 31.59
17.52 52 Week Range 45.00
Market Cap
Previous Close
31.60
Open
31.15
Last Trade Time
Financial Volume
$ 11,144,343
VWAP
30.8892
Average Volume (3m)
551,143
Shares Outstanding
26,915,243
Dividend Yield
-
PE Ratio
-28.06
Earnings Per Share (EPS)
-1.1
Revenue
166.8M
Net Profit
-29.73M

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of... Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
San Diego, California, USA
Founded
1970
Arcturus Therapeutics Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARCT. The last closing price for Arcturus Therapeutics was $31.60. Over the last year, Arcturus Therapeutics shares have traded in a share price range of $ 17.52 to $ 45.00.

Arcturus Therapeutics currently has 26,915,243 shares outstanding. The market capitalization of Arcturus Therapeutics is $834.10 million. Arcturus Therapeutics has a price to earnings ratio (PE ratio) of -28.06.

Arcturus Therapeutics (ARCT) Options Flow Summary

Overall Flow

Bullish

Net Premium

733k

Calls / Puts

200.00%

Buys / Sells

200.00%

OTM / ITM

50.00%

Sweeps Ratio

0.00%

ARCT Latest News

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

ARCT-032 is safe and well tolerated with no serious adverse events (SAEs) in 36 study participants, including 4 adults with cystic fibrosis (CF) Phase 1b interim data includes a CF participant...

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024 First four CF patients demonstrated an average improvement of 4% FEV1 after two...

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and...

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine PR Newswire KING OF PRUSSIA, Pa. and SAN DIEGO, May 20...

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine

Data follow the approval of the world’s first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior...

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities...

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Commercial manufacture of Kostaive® on track for delivery of initial 4 million doses in Q3 Kostaive® European Marketing Authorization Application approval decision expected Q3 Multiple Kostaive®...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-10.38-24.726060028641.9842.4229.7399010631.77620283CS
41.13.6065573770530.54529.2264155634.89547088CS
12-1.44-4.358353510933.044525.4155114331.59611594CS
265.3120.19779383826.294525.4148707533.27281161CS
522.8910.066179031728.714517.5245749630.31539705CS
156-3.13-9.0123812266134.7364.973511.754065929.18875455CS
26024.72359.3023255816.88129.715.7557230838.96076116CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

ARCT Discussion

View Posts
Monksdream Monksdream 3 months ago
ARCT 10Q due March 7
👍️0
Monksdream Monksdream 4 months ago
ARCT new 52 week high
👍️0
Monksdream Monksdream 10 months ago
Arcturus Therapeutics (ARCT)
icon-fall
19%
Shares of Arcturus Therapeutics traded down ~19% on Tuesday after the company announced4 lower-than-expected revenue and earnings for the second quarter. According to management, revenue declined in response to the termination of two agreements, one with Vinbiocare and another with the Israeli Ministry of Health. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
👍️0
Monksdream Monksdream 11 months ago
Arcturus Therapeutics Holdings Inc NASDAQ: ARCT

GoSymbol lookup
Health Care : Biotechnology | Small Cap GrowthCompany profile
Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform







and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.

Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
Arcturus Therapeutics (ARCT)
icon-rise-1
15%
Shares of Arcturus Therapeutics traded up ~15% on Friday after the company’s vaccine, ARCT-154, demonstrated6 an improvement in immunogenicity—43% more neutralizing antibodies at a lower dose than Comirnaty®. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
👍️0
IOUBLOKE1 IOUBLOKE1 2 years ago
Silence is golden ARC
👍️0
IOUBLOKE1 IOUBLOKE1 2 years ago
Wow big after hours green buy
👍️0
IOUBLOKE1 IOUBLOKE1 2 years ago
Spike delivers in Canada 400 million does
👍️0
make it happen make it happen 3 years ago
http://archive.fast-edgar.com/20210812/A2Z2M22C3Z2232K222JN2CZ272FUV22SE232/ another company that directs them selling out potentially seems like a big negative along with many downgrades over $20.00 less than current PPS
👍️0
Smknf250 Smknf250 3 years ago
I don’t see any filing that reflects that. Where do you see it?
👍️0
make it happen make it happen 3 years ago
Director sold 725,000 shares @ $55.44 and 25,000 @ $45.83 total of 800,000 shares

Capitalization at it's finest, run for the hills. imho

bounce off 30's then into 20's
👍️0
make it happen make it happen 3 years ago
B. Wriley Price target $27.00. Price Per Share PPS is $47.00. Only $20.00 to drop to hit raised price target.
👍️0
make it happen make it happen 3 years ago
$1.40* opps

1-7 R/S

Sold drug in a few years will prob do another one sadly
👍️0
make it happen make it happen 3 years ago
Don't forget was like $1.10 at one point. Only 2 mil Revenue VS 2.7 expected.. while losing 56.4 mil in the second quarter or over 225,000,000 million loss for the year.

-$225,000,000 vs maybe 4 mil on a good year

Downgraded to under preform

Sold the drug now have nada

Also had nice size R/S in the past
👍️0
make it happen make it happen 3 years ago
Posted Revenue of $2 million vs estimated 2.7 mil.

Loss of $56.4 million second quarter only.

Huge differences

Sold the drug... No mo

Down graded to underperform
👍️0
make it happen make it happen 3 years ago
Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Oh no...
👍️0
dinogreeves dinogreeves 3 years ago
ARCT the next NVAX.
👍️0
Cosa Cosa 3 years ago
might be getting squeezed, the float is so low.
👍️0
Cosa Cosa 3 years ago
wow this is pumping
👍️0
Atown62 Atown62 3 years ago
Thoughts now?
👍️0
Clemdane Clemdane 3 years ago
Still long here. This is a looong term buy. Disappointing that we got that massive haircut, but we've had them before and recovered. It's the nature of this volatile sector.
👍️0
Atown62 Atown62 3 years ago
Well?
👍️0
lecorb lecorb 3 years ago
In TDAmeritrade. TIPRANKS 7 SCROE PT: $88.25
Analyst Ratings, Moderate Buy! Last actualitation!
Based on the 10 sell-sidetooltipClick this button to read the definition of sell-side analysts who offered a 12-month price target in the last three months. Analysts predict a(n) 122.80% increase from today.
Kumaraguru Raja
Brookline Capital Markets
5Stars target $102.00rankingBuyanalystAction
Maintained date 2 days ago
analyst
Steven Seedhouse
Raymond James
5 Stars target ranking Hold analystAction Downgraded date 2 days ago
analyst
Yasmeen Rahimi
Piper Sandler
5Star target $140.00 ranking Buy analystAction Maintained
date 2 days ago
analyst
Seamus Fernandez
Guggenheim
5 Stars target -- ranking Buy analystAction Maintained date
2 days ago
Madhu Kumar
Robert W. Baird
5 Stars target $69.00 ranking Hold analystAction Downgraded
date
2 days ago
analyst
Elemer Piros
Roth Capital
5 Stars target $77.00 ranking Sell analystAction Maintained
date 2 days ago
Mayank Mamtani
B.Riley Financial
5 Stars target $138.00 ranking Buy analystAction Maintained
date 2 days ago
analyst
Yigal Nochomovitz
Citigroup
5Stars target $133.00 ranking Buy analystAction Maintained
date 17 days ago
👍️0
sanderburwil sanderburwil 3 years ago
Nope- was just a good “tax dump day” excuse today. Not holding- but really tempted- can only see upwards from here. Cathy woods didn’t sell a share today. Tells you something..
👍️0
Willymon Willymon 3 years ago
ARCT - Re-enter in the 30's. 34-37 seems to be my gate with this one.


The ol' "buy the rumor, sell the news" strikes again.


Or, today is last day to sell for 2020 taxes -- Dump day.


Take your pick.


It's a pandemic market and more crazy and unexpected things to come.


Remember, ARCT has a lot more to offer than just COVID solutions.


Their tech enables many other biotech companies delivery and replication methods.


ARCT has established a 52-wk high of $130.


Many think it will go past that.

👍️0
ClayTrader ClayTrader 3 years ago
* * $ARCT Video Chart 12-29-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Clemdane Clemdane 4 years ago
Wish I had flipped it. Hindsight is 20/20.
👍️0
Willymon Willymon 4 years ago
ARCT - Me as well. Been in-n-out four times with profits every time.


When I talk to others they never heard of ARCT.


Ready for the next leg.
👍️0
Clemdane Clemdane 4 years ago
I'm still in - going to see where the ride takes me
👍️0
Willymon Willymon 4 years ago
ARCT - Still going but nobody on iHub seems aware.


Some on Stocktwits saying this is going to $500-700.


I get 10x plays often, but this is a big 10x for sure.
👍️0
whytestocks whytestocks 4 years ago
JUST IN: $ARCT Why Arcturus Therapeutics Stock Soared Today

Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) were soaring 12.7% higher as of 3:28 p.m. EST on Tuesday. The big jump came after the clinical-stage biotech provided its third-quarter update following the market close on Monday. Investors were less interested in Arcturus' fi...

In case you are interested ARCT - Why Arcturus Therapeutics Stock Soared Today
👍️0
whytestocks whytestocks 4 years ago
Breaking News: $ARCT Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

LUNAR® lipids undetectable in plasma 48 hours following drug administration ARCT-810 well tolerated at doses up to 0.3 mg/kg, 0.4 mg/kg cohort to be completed in Q4 Initial dosing of OTC-deficient patients at a U.S. clinical site expected in Q4 Arcturus ...

Find out more ARCT - Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
👍️0
Clemdane Clemdane 4 years ago
I'm more amazed that anyone posted on this board. But I agree on the breakout!
👍️0
Willymon Willymon 4 years ago
ARCT - In it to win it.
👍️0
Biggiee Biggiee 4 years ago
Breakout! Blue skies.
👍️0
Clemdane Clemdane 4 years ago
Wow! Someone posted on the ARCT board. Thank you very much. I like your chart. I will put my faith in Fibonacci!
👍️0
TFMG TFMG 4 years ago
$ARCT | #ArcturusTherapeutics Breakout Alert



Potential long above $63.00
Upside Fibonacci target zone $76.00


👍️0
Clemdane Clemdane 4 years ago
Hello silent ARCT board. Just a message to say I am still here! Still long ARCT.
👍️0
Clemdane Clemdane 4 years ago
That's what I thought. Thank you.
👍️0
Willymon Willymon 4 years ago
$ARCT - Doesn't look like the two are comparable.

$ARCT's self replicating delivery method along with the protein they are developing to block the keyholes in the host (humans) the spikes on viruses need to infect the host is a unique approach. Can't spike into a receiving host keyhole, no infection or replication. Game over.

$ARCT would be one shot as a cure for nearly all viruses, including the common flu.

I'm also a little weary with all these biotechs promising cures so soon.

Rhinovirus(Flu/common cold) still has no vaccine which they have been working to cure since the 1950's.

$ARCT thinks they have the total solution.

👍️0
Clemdane Clemdane 4 years ago
Hey do you know anywhere with a good competitive analysis of ARCT vs. the Oxford University vaccine?
👍️0
Clemdane Clemdane 4 years ago
It's truly incredible. I'm thrilled to be here.
👍️0
Willymon Willymon 4 years ago
$ARCT - News out today. How you feeling about those 13's now?
👍️0
pix pix 4 years ago
Shortly they hopefully will give some details to preclinical studies...
If positive, watch out...
👍️0
Willymon Willymon 4 years ago
$ARCT - Singapore has set and is setting the example to follow in all this.

The fact that they selected $ARCT to develop a cure is very telling.

Arcturus announced that it is partnering with Duke-NUS, a partnership between the Duke University School of Medicine and the National University of Singapore, to develop a COVID-19 vaccine to prevent infection by the coronavirus. The government of Singapore will pay for the vaccine's development -- $10 million to be paid part up-front, part upon achievement of unspecified "development milestones." And Singapore will get first dibs on any vaccines produced (plus potential royalties on vaccine sales outside of Singapore).Link>

👍️0
pix pix 4 years ago
If approved in Singapore, they will get access to many Asian countries....
👍️0
Clemdane Clemdane 4 years ago
Incredible. I have it in an IRA. Going to try to get more.
👍️0
Willymon Willymon 4 years ago
$ARCT - $13.90 is sooner. Nobody here is even aware of them. And, with only 1100 on stocktwits, nobody there is aware.

If you buy at $50 and it goes to $110, you're still in profit. But, now we're into the "What IF" game. Have to be long on $ARCT.

If they come up with the Covid-19 vaccine, then that also means they also cured thousands of other viruses.

Their method is to provide humans with a way to clog the keyholes that the spikes on viruses need to plug into to infect and replicate.

They don't patent some of their methods on purpose because a patent must show exactly how something works. This is to their advantage so other biotech companies have to go figure it out on their own. Trade secret.

👍️0
Clemdane Clemdane 4 years ago
That makes sense. Yes, I saw the offering. I got in around $13.90. I wish I had gotten in sooner
👍️0
Willymon Willymon 4 years ago
$ARCT - PPS too high for iHubers and is not a OTC stock.

6 Followers iHub
1,091 Followers StockTwits (Only ~40 new followers in three weeks)
4,475 Followers SeekingAlpha (Their board is also inactive)


You said you are in $INO

596 Followers iHub
46,075 Followers StockTwits
43,563 Followers SeekingAlpha


Anything over $7, the chatter will be somewhere else. Especially if its not a OTC stock.

But, $ARCT is very promising for an ultra vaccine solution to the world.

Did you catch that they sold 2MM shares at $10/share to two investment firms as an additional capital raise. Listen to their last call on SeekingAlpha if you haven't already.

To me, than means if those firms did their homework, then they are looking for 10x return.

That means $ARCT which is at $17 will go to over +$100 if they can pull it off.

Not only are they working for vaccine solution, but they are doing it in a way that will scale production to supply the world, quick.

Think of the volume in the syringe of your last flu shot and then with $ARCT solution you would only need 1/100 the dose. I think its actually less - 1/1000?

Been buying since it was at $12

Sure would be nice to have 1MM shares of $ARCT






👍️0
Clemdane Clemdane 4 years ago
Does ARCT have to go to $25 for people here to notice it?
👍️0

Your Recent History

Delayed Upgrade Clock